Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration…
Read More
Publications Archive for ‘Fragile X’
Tweets
Autifony CEO Charles Large will be speaking in the Pharmaceutical Pipeline session at this year’s SIRS conference i… https://t.co/L9WSnWTMbV
We are currently recruiting a JNR Medicinal Chemist and a Quality Systems Administrator, for a full job description… https://t.co/6VEPliT1Fg
Autifony CEO Charles Large will be speaking at the a webinar ‘Fragile X syndrome – in pursuit of a cure’ World Frag… https://t.co/DPw8f5LPMN
© Copyright 2022 Autifony Therapeutics
